HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback